Abstract
CD44 is a marker of tumour-initiating cells and is upregulated in invasive breast carcinoma; however, its role in the cancer progression is unknown. Here, we show that antibody-mediated CD44-targeting in human breast cancer xenografts (HBCx) significantly reduces tumour growth and that this effect is associated to induction of growth-inhibiting factors. Moreover, treatment with this antibody prevents tumour relapse after chemotherapy-induced remission in a basal-like HBCx. © 2009 Cancer Research.
Author supplied keywords
Cite
CITATION STYLE
Marangoni, E., Lecomte, N., Durand, L., De Pinieux, G., Decaudin, D., Chomienne, C., … Poupon, M. F. (2009). CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. British Journal of Cancer, 100(6), 918–922. https://doi.org/10.1038/sj.bjc.6604953
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.